(57 days)
The Voxar 3D product family is a suite of products that is intended to provide tools for the reading and review of a DICOM compliant series of medical images which can be interpreted as representing a volume of data. These tools are meant for the use of trained medical imaging professionals to aid in their reading and review of such data.
The Voxar 3D product family provides several levels of functionality:
- Basic analysis tools used on a daily basis, such as 2D review, orthogonal Multi Planar Reconstructions . (MPRs), oblique MPRs, curved/cross-curved MPRs, slab MPRs, AvelP, MIP, MinIP, measurements, annotations, reporting, and distribution.
- Tools for in-depth analysis, such as regional segmentation of anatomical structures within the image data. . endoscopic review, color volume rendering of finite thickness data cross-sections, 3D review of data volumes, path definition through vascular and other tubular structures and boundary detection.
- Specialist tools and workflow enhancements for specific clinical applications which provide directed workflows. custom User Interfaces, and special measurement and reporting functions optimized for the specific clinical applications. Specialized clinical applications include:
- Colon Screening (which is intended for the screening of patients for colonic polyps, tumours and other o lesions using tomographic Colonography),
- Vessel Analysis (which is intended for the qualitative and quantitative analysis of tomographic o angiographic studies to evaluate occlusive and aneurismal diseases and the effectiveness of stents and stent grafts)
- Coronary Artery Analysis (which is intended for the qualitative and quantitative analysis of coronary o arteries to evaluate occlusive and aneurismal disease),
- Functional Cardiac Analysis (which is intended to evaluate the functional characteristics of the heart), O
- PET-CT Reading (which is intended for analysis of lesions using FDG imaging from hybrid PET-CT o scanners)
This 510(k) submission (K070831) for the Voxar 3D Enterprise with ColonMetrix and PET/CT Perfusion, a Picture Archiving and Communications System (PACS), does not contain the acceptance criteria or a detailed study proving the device meets acceptance criteria.
The document is a letter from the FDA to BarcoView MIS Edinburgh, confirming that their device is substantially equivalent to legally marketed predicate devices. It primarily focuses on regulatory compliance and the device's indications for use.
Therefore, I cannot provide the requested information from the provided text. The document is a regulatory approval letter, not an engineering or clinical study report.
Here's what each requested piece of information would require, and why it's not present in this document:
- A table of acceptance criteria and the reported device performance: This would typically be found in a verification and validation (V&V) report, a clinical study report, or a comprehensive technical specification. This regulatory letter does not include such details.
- Sample sized used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective): This information would be specific to the testing performed to demonstrate device performance. It is not included in this FDA approval letter.
- Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience): This is a detail of ground truth establishment for a performance study, which is absent here.
- Adjudication method (e.g. 2+1, 3+1, none) for the test set: Another detail typically found in a study design section, not in a regulatory approval letter.
- If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance: The document mentions "Specialist tools and workflow enhancements for specific clinical applications" including "Colon Screening" and "PET-CT Reading," which might suggest such studies were performed. However, the results, methods, and effect sizes of any MRMC studies are not provided in this document.
- If a standalone (i.e. algorithm only without human-in-the-loop performance) was done: Similar to MRMC studies, the details of any standalone performance assessment are not available in this letter.
- The type of ground truth used (expert consensus, pathology, outcomes data, etc.): This is study-specific information and is not included.
- The sample size for the training set: This relates to the development of the device's algorithms, not its regulatory approval based on substantial equivalence. This information is not in the document.
- How the ground truth for the training set was established: Again, this is a detail of algorithm development, not present in this regulatory letter.
In summary, the provided document is a notification of FDA clearance based on substantial equivalence to a predicate device. It does not contain the detailed technical or clinical study data that would describe acceptance criteria or prove device performance.
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image shows a circular logo with text around the perimeter and a stylized design in the center. The text reads "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" in a circular arrangement. The central design features three curved lines that resemble a stylized human figure or a symbol representing health and well-being. The logo appears to be a seal or emblem associated with the U.S. Department of Health and Human Services.
DEPARTMENT OF HEALTH & HUMAN SERVICES
Food and Drug Administration 9200 Corporate Blvd. Rockville MD 20850
BarcoView MIS Edinburgh % Mr. Jeff D. Rongero Senior Project Engineer Underwriters Laboratories, Inc. 12 Laboratory Drive Research Triangle Park, NC 27709
MAY 2 2 2007
Re: K070831
Trade/Device Name: Voxar 3D Entreprise with ColonMetrix and PET/CT Perfusion Regulation Number: 21 CFR 892.2050 Regulation Name: Picture archiving and communications system Regulatory Class: II Product Code: LLZ Dated: May 4, 2007 Received: May 9, 2007
Dear Mr. Rongero:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for. use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Image /page/0/Picture/10 description: The image shows a circular logo with the text "1906-2006" at the top. Below that is the acronym "FDA" in large, bold letters. Underneath the acronym, the word "Centennial" is written in a cursive font. At the bottom of the logo, there are some smaller characters that are difficult to read.
Protecting and Promoting Public Health
{1}------------------------------------------------
Page 2 -
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:
| 21 CFR 876.xxx | (Gastroenterology/Renal/Urology) | 240-276-0115 |
|---|---|---|
| 21 CFR 884.xxx | (Obstetrics/Gynecology) | 240-276-0115 |
| 21 CFR 894.xxx | (Radiology) | 240-276-0120 |
| Other | 240-276-0100 |
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150
or at its Internet address http://www.fda.gov/cdrl/industry/support/index.html.
Sincerely yours,
Nancy Cbrogdon
Nancy C. Brogdon Director, Division of Reproductive, Abdominal, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications For Use
Applicant:
BarcoView MIS Edinburgh, Bonnington Bond, 2 Anderson Place, Edinburgh, EH6 5NP, UK.
510(k) Number (if known): Ko70831 Unknown
Device Name:
Voxar 3D Product Family
Indications For Use:
The Voxar 3D product family is a suite of products that is intended to provide tools for the reading and review of a DICOM compliant series of medical images which can be interpreted as representing a volume of data. These tools are meant for the use of trained medical imaging professionals to aid in their reading and review of such data.
The Voxar 3D product family provides several levels of functionality:
- Basic analysis tools used on a daily basis, such as 2D review, orthogonal Multi Planar Reconstructions . (MPRs), oblique MPRs, curved/cross-curved MPRs, slab MPRs, AvelP, MIP, MinIP, measurements, annotations, reporting, and distribution.
- Tools for in-depth analysis, such as regional segmentation of anatomical structures within the image data. . endoscopic review, color volume rendering of finite thickness data cross-sections, 3D review of data volumes, path definition through vascular and other tubular structures and boundary detection.
- Specialist tools and workflow enhancements for specific clinical applications which provide directed workflows. custom User Interfaces, and special measurement and reporting functions optimized for the specific clinical applications. Specialized clinical applications include:
- Colon Screening (which is intended for the screening of patients for colonic polyps, tumours and other o lesions using tomographic Colonography),
- Vessel Analysis (which is intended for the qualitative and quantitative analysis of tomographic o angiographic studies to evaluate occlusive and aneurismal diseases and the effectiveness of stents and stent grafts)
- Coronary Artery Analysis (which is intended for the qualitative and quantitative analysis of coronary o arteries to evaluate occlusive and aneurismal disease),
- Functional Cardiac Analysis (which is intended to evaluate the functional characteristics of the heart), O
- PET-CT Reading (which is intended for analysis of lesions using FDG imaging from hybrid PET-CT o scanners)
This product is not intended for use with or for the primary diagnostic interpretation of Mammography images.
Prescription Use (Part 21 CFR 801 Subpart D) OR
Over-The-counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE)
Nancy Brogdon
510(k) Submission Page C2
§ 892.2050 Medical image management and processing system.
(a)
Identification. A medical image management and processing system is a device that provides one or more capabilities relating to the review and digital processing of medical images for the purposes of interpretation by a trained practitioner of disease detection, diagnosis, or patient management. The software components may provide advanced or complex image processing functions for image manipulation, enhancement, or quantification that are intended for use in the interpretation and analysis of medical images. Advanced image manipulation functions may include image segmentation, multimodality image registration, or 3D visualization. Complex quantitative functions may include semi-automated measurements or time-series measurements.(b)
Classification. Class II (special controls; voluntary standards—Digital Imaging and Communications in Medicine (DICOM) Std., Joint Photographic Experts Group (JPEG) Std., Society of Motion Picture and Television Engineers (SMPTE) Test Pattern).